Avid Radiopharmaceuticals
Joachim Berkner is an experienced professional in the pharmaceutical industry, currently serving as the Director of CMC Project Management at Avid Radiopharmaceuticals since 2017. Previously, Joachim held the position of Director of Development at Siegfried (USA) from 2007 to 2016 and was Manager of Chemistry Services at Noramco, Inc. between 1999 and 2007. Additionally, Joachim worked as the Director of Research and Development at BioShield Technologies from 1997 to 1999.
Avid Radiopharmaceuticals
1 followers
At Avid, a wholly owned subsidiary of Eli Lilly and Company, our mission is to develop new molecular imaging agents capable of changing the medical management of significant chronic human diseases. We have assembled an outstanding management team with extensive imaging and CNS development experience to help make pre-symptomatic disease detection a reality. Avid's pipeline of imaging compounds has the potential to dramatically alter the clinical course of challenging conditions such as Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's disease and Diabetes Mellitus. This may be possible because our molecular imaging compounds may be able to detect the first stages of pathological change; allowing early treatment and management of people at risk - perhaps before before symptoms of disease can develop.